38% Fewer Overdose Deaths Than the Peak. The System That Caused Them Hasn't Changed.

NVSS provisional data released this month projects 69,147 drug overdose deaths for the 12 months ending January 2026. That’s 13.2 percent fewer than the prior year, and 38.4 percent below the peak. The data has been everywhere — as evidence of progress, as evidence of what policy can accomplish, as evidence of an epidemic turning a corner.

The number is real. The narrative around it is not.

The treatment gap in the United States — the gap between people with opioid use disorder and people receiving evidence-based medication for it — has not meaningfully closed. Fewer than 20 percent of people with OUD receive any form of MOUD, a number that has barely budged in years. The SAMHSA funding cuts, Medicaid enrollment losses, and behavioral health workforce gaps that were already compressing the supply side of treatment did not suddenly reverse in 2025. The clinic-only methadone system that Senators Markey and Paul are trying to reform has not changed. The treatment system did not improve its way to 38 percent fewer deaths.

What changed is the drug supply.

The primary driver of the decline, according to researchers cited in the NVSS data release, is a reduction in fentanyl potency linked to Chinese export controls on key precursor chemicals — controls negotiated in 2023 and 2024 that constrained cartel chemistry. When what’s in the bag becomes slightly less lethal, slightly more people survive. The FDA approval of a third OTC naloxone product (Rextovy) in June, joining Narcan and RiVive, also contributed. Naloxone now available at pharmacies nationwide. More reversals. More people alive who weren’t alive before.

That’s worth something. People breathing today who would not be otherwise.

What it is not worth is complacency. Sixty-nine thousand deaths is still the third-highest annual total in this epidemic’s history. The ~190 deaths per day that represents is still more than double what it was in 2010. And the factors driving the decline — precursor chemistry policy, naloxone expansion — are not factors that treatment systems control. If cartel supply chains adapt to the precursor controls, as they have adapted to every prior disruption, the potency climbs back and the death count follows. The system will not have changed because the number got better.

A 38 percent decline in overdose deaths attributed primarily to a reduction in drug supply potency is a stay of execution, not a reversal of the epidemic. We should be grateful for every day it holds. We should be building like it won’t.